Atlas Trials

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Clinical trial NCT00720629 · TERMINATED

Trial details

NCT number
NCT00720629
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Graft Versus Host Disease
Start date
2007-12-01
Primary completion
2013-12-01
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.